nach oben

Erschienen in:

26.05.2023 | Diagnostic Neuroradiology

MRI and Trouillas’ grading system of pituitary tumors: the usefulness of T2 signal intensity volumetric values

verfasst von: Rosalinda Calandrelli, Fabio Pilato, Gabriella D’Apolito, Stefano Schiavetto, Marco Gessi, Quintino Giorgio D’Alessandris, Liverana Lauretti, Simona Gaudino

Erschienen in: Neuroradiology | Ausgabe 11/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To classify pituitary macroadenomas according to the Trouillas’ grading system; to compare this grading system with T2 values of volumetric signal intensity to determine T2 values able to predict the final grade.

Methods

A total of 106 patients with macroadenomas were grouped according to the grading system score combining proliferation and invasiveness criteria of Trouillas’ classification. Normalized volumetric signal intensity values were extracted from coronal T2-weighted images (nT2mean, nT2Max, nT2min) and were compared with the final grading score system.

Results

Thirty-three patients were in grade 1a (non-invasive, non-proliferative tumors), 17 patients in grade 1b (non-invasive, proliferative tumors), 36 patients in grade 2a (invasive, non-proliferative tumors), and 20 patients in grade 2b (invasive, proliferative tumors). No patient was in grade 3 (metastatic tumors). nT2Max and nT2min were the best quantitative values to discriminate invasive from non-invasive grades; in invasive grades, nT2Max intensity values were higher, and nT2min intensity values were lower than in non-invasive grades.

Receiver operating characteristic analysis of nT2 values showed that nT2min values had a better diagnostic performance than nT2Max values because they allowed differentiating with a moderate accuracy invasive tumors (2a or 2b grades) from both non-invasive proliferative tumors (1b) and non-invasive-non proliferative tumors (1a) (2a vs 1b: AUC_nT2min = 0.78, 2b vs 1b: AUC_nT2min = 0.72, 2a vs 1a: AUC_nT2min = 0.72, 2b vs 1a AUC_nT2min = 0.69).

Conclusion

Volumetric nT2Max and nT2min values of MRI might be practical and non-invasive markers for assessing tumor invasiveness although nT2 min signal intensity values have more effects in discriminating tumor’s invasive behavior.

Chen Y, Wang CD, Su ZP et al (2012) Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Neuroendocrinology 96:333–342. https://doi.org/10.1159/000339823CrossRefPubMed

Mercado M, Melgar V, Salame L, Cuenca D (2017) Clinically non-functioning pituitary adenomas: pathogenic, diagnostic and therapeutic aspects. Endocrinol Diabetes Nutr 64:384–395. https://doi.org/10.1016/j.endinu.2017.05.009CrossRefPubMed

Fernández-Balsells MM, Murad MH, Barwise A et al (2011) Natural history of nonfunctioning pituitary adenomas and incidentalomas: a systematic review and metaanalysis. J Clin Endocrinol Metab 96:905–912. https://doi.org/10.1210/jc.2010-1054CrossRefPubMed

Miao Y, Zong M, Jiang T et al (2016) A comparative analysis of ESM-1 and vascular endothelial cell marker (CD34/CD105) expression on pituitary adenoma invasion. Pituitary 19:194–201. https://doi.org/10.1007/s11102-015-0698-6CrossRefPubMedPubMedCentral

Ntali G, Wass JA (2018) Epidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas. Pituitary 21:111–118. https://doi.org/10.1007/s11102-018-0869-3CrossRefPubMed

Fernandez A, Karavitaki N, Wass JAH (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72:377–382. https://doi.org/10.1111/j.1365-2265.2009.03667.xCrossRefPubMed

Micko ASG, Wöhrer A, Wolfsberger S, Knosp E (2015) Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. J Neurosurg 122:803–811. https://doi.org/10.3171/2014.12.JNS141083CrossRefPubMed

WHO Classification of Tumours Editorial Board (2021) World health organization classification of tumours of the central nervous system. 5th ed. Lyon: International Agency for Research on Cancer

Lim CT, Korbonits M (2018) Update on the clinicopathology of pituitary adenomas. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol 24:473–488. https://doi.org/10.4158/EP-2018-0034CrossRef

10.

Lopes MBS (2017) The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol (Berl) 134:521–535. https://doi.org/10.1007/s00401-017-1769-8CrossRefPubMed

11.

Ruggeri RM, Costa G, Simone A et al (2012) Cell proliferation parameters and apoptosis indices in pituitary macroadenomas. J Endocrinol Invest 35:473–478. https://doi.org/10.3275/7905CrossRefPubMed

12.

Serioli S, Doglietto F, Fiorindi A et al (2019) Pituitary adenomas and invasiveness from anatomo-surgical, radiological, and histological perspectives: a systematic literature review. Cancers 11:E1936. https://doi.org/10.3390/cancers11121936CrossRef

13.

Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33:610–617; discussion 617-618. https://doi.org/10.1227/00006123-199310000-00008CrossRefPubMed

14.

Miermeister CP, Petersenn S, Buchfelder M et al (2015) Histological criteria for atypical pituitary adenomas - data from the German pituitary adenoma registry suggests modifications. Acta Neuropathol Commun 3:50. https://doi.org/10.1186/s40478-015-0229-8CrossRefPubMedPubMedCentral

15.

Ghadir M, Khamseh ME, Panahi-Shamsabad M et al (2020) Cell proliferation, apoptosis, and angiogenesis in non-functional pituitary adenoma: association with tumor invasiveness. Endocrine 69:596–603. https://doi.org/10.1007/s12020-020-02366-6CrossRefPubMed

16.

Glebauskiene B, Liutkeviciene R, Vilkeviciute A et al (2018) Association of Ki-67 labelling index and IL-17A with pituitary adenoma. BioMed Res Int 2018:7490585. https://doi.org/10.1155/2018/7490585CrossRefPubMedPubMedCentral

17.

Grimm F, Maurus R, Beschorner R et al (2019) Ki-67 labeling index and expression of p53 are non-predictive for invasiveness and tumor size in functional and nonfunctional pituitary adenomas. Acta Neurochir (Wien) 161:1149–1156. https://doi.org/10.1007/s00701-019-03879-4CrossRefPubMed

18.

Hasanov R, Aydoğan Bİ, Kiremitçi S et al (2019) The prognostic roles of the Ki-67 proliferation index, P53 expression, mitotic index, and radiological tumor invasion in pituitary adenomas. Endocr Pathol 30:49–55. https://doi.org/10.1007/s12022-018-9563-2CrossRefPubMed

19.

Bai Y, Shen Y, Chen R et al (2021) Magnetic resonance fingerprinting for preoperative differentiation between gonadotroph and non-gonadotroph pituitary macroadenomas. Eur Radiol 31:8420–8428. https://doi.org/10.1007/s00330-021-07950-6CrossRefPubMed

20.

Conficoni A, Feraco P, Mazzatenta D et al (2020) Biomarkers of pituitary macroadenomas aggressive behaviour: a conventional MRI and DWI 3T study. Br J Radiol 93:20200321. https://doi.org/10.1259/bjr.20200321CrossRefPubMedPubMedCentral

21.

Potorac I, Petrossians P, Daly AF et al (2015) Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocr Relat Cancer 22:169–177. https://doi.org/10.1530/ERC-14-0305CrossRefPubMed

22.

Lv L, Hu Y, Yin S et al (2018) Clinically aggressive phenotype: a clinicopathological case series of atypical pituitary adenomas. Clin Neurol Neurosurg 167:93–98. https://doi.org/10.1016/j.clineuro.2018.02.001CrossRefPubMed

23.

Trouillas J, Roy P, Sturm N et al (2013) A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol (Berl) 126:123–135. https://doi.org/10.1007/s00401-013-1084-yCrossRefPubMed

24.

Connor SEJ, Wilson F, Hogarth K (2014) Magnetic resonance imaging criteria to predict complete excision of parasellar pituitary macroadenoma on postoperative imaging. J Neurol Surg Part B Skull Base 75:41–46. https://doi.org/10.1055/s-0033-1353362CrossRef

25.

Yiping L, Ji X, Daoying G, Bo Y (2016) Prediction of the consistency of pituitary adenoma: a comparative study on diffusion-weighted imaging and pathological results. J Neuroradiol J Neuroradiol 43:186–194. https://doi.org/10.1016/j.neurad.2015.09.003CrossRefPubMed

26.

Boxerman JL, Rogg JM, Donahue JE et al (2010) Preoperative MRI evaluation of pituitary macroadenoma: imaging features predictive of successful transsphenoidal surgery. AJR Am J Roentgenol 195:720–728. https://doi.org/10.2214/AJR.09.4128CrossRefPubMed

27.

Khant ZA, Azuma M, Kadota Y et al (2019) Evaluation of pituitary structures and lesions with turbo spin-echo diffusion-weighted imaging. J Neurol Sci 405:116390. https://doi.org/10.1016/j.jns.2019.07.008CrossRefPubMed

28.

Kamimura K, Nakajo M, Fukukura Y et al (2016) Intravoxel incoherent motion in normal pituitary gland: initial study with turbo spin-echo diffusion-weighted imaging. AJNR Am J Neuroradiol 37:2328–2333. https://doi.org/10.3174/ajnr.A4930CrossRefPubMedPubMedCentral

29.

Chang N, Grayson JW, Mangussi-Gomes J et al (2021) Assessment of magnetic resonance imaging criteria for the diagnosis of cavernous sinus invasion by pituitary tumors. J Clin Neurosci Off J Neurosurg Soc Australas 90:262–267. https://doi.org/10.1016/j.jocn.2021.06.010CrossRef

30.

Zeynalova A, Kocak B, Durmaz ES et al (2019) Preoperative evaluation of tumour consistency in pituitary macroadenomas: a machine learning-based histogram analysis on conventional T2-weighted MRI. Neuroradiology 61:767–774. https://doi.org/10.1007/s00234-019-02211-2CrossRefPubMed

31.

Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29–36. https://doi.org/10.1148/radiology.143.1.7063747CrossRefPubMed

32.

Swets JA (1988) Measuring the accuracy of diagnostic systems. Science 240:1285–1293. https://doi.org/10.1126/science.3287615CrossRefPubMed

33.

Mete O, Asa SL (2012) Clinicopathological correlations in pituitary adenomas. Brain Pathol Zurich Switz 22:443–453. https://doi.org/10.1111/j.1750-3639.2012.00599.xCrossRef

34.

Di Ieva A, Rotondo F, Syro LV et al (2014) Aggressive pituitary adenomas--diagnosis and emerging treatments. Nat Rev Endocrinol 10:423–435. https://doi.org/10.1038/nrendo.2014.64CrossRefPubMed

35.

Rindi G, Klimstra DS, Abedi-Ardekani B et al (2018) A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol Off J U S Can Acad Pathol Inc 31:1770–1786. https://doi.org/10.1038/s41379-018-0110-yCrossRef

36.

Hentschel SJ, McCutcheon Lan E, Moore W, Durity FA (2003) P53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas. Can J Neurol Sci J Can Sci Neurol 30:215–219. https://doi.org/10.1017/s0317167100002614CrossRef

37.

Thapar K, Kovacs K, Scheithauer BW et al (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38:99–106; discussion 106-107. https://doi.org/10.1097/00006123-199601000-00024CrossRefPubMed

38.

Trouillas J, Jaffrain-Rea M-L, Vasiljevic A et al (2020) Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician’s questions. Rev Endocr Metab Disord 21:243–251. https://doi.org/10.1007/s11154-020-09562-9CrossRefPubMed

39.

Chatzellis E, Alexandraki KI, Androulakis II, Kaltsas G (2015) Aggressive pituitary tumors. Neuroendocrinology 101:87–104. https://doi.org/10.1159/000371806CrossRefPubMed

40.

Zaidi HA, Cote DJ, Dunn IF, Laws ER (2016) Predictors of aggressive clinical phenotype among immunohistochemically confirmed atypical adenomas. J Clin Neurosci Off J Neurosurg Soc Australas 34:246–251. https://doi.org/10.1016/j.jocn.2016.09.014CrossRef

41.

Gruppetta M, Vassallo J (2016) Epidemiology and radiological geometric assessment of pituitary macroadenomas: population-based study. Clin Endocrinol (Oxf) 85:223–231. https://doi.org/10.1111/cen.13064CrossRefPubMed

42.

Nishioka H, Inoshita N (2018) New WHO classification of pituitary adenomas (4th edition): assessment of pituitary transcription factors and the prognostic histological factors. Brain Tumor Pathol 35:57–61. https://doi.org/10.1007/s10014-017-0307-7CrossRefPubMed

43.

Bahuleyan B, Raghuram L, Rajshekhar V, Chacko AG (2006) To assess the ability of MRI to predict consistency of pituitary macroadenomas. Br J Neurosurg 20:324–326. https://doi.org/10.1080/02688690601000717CrossRefPubMed

44.

Thotakura AK, Patibandla MR, Panigrahi MK, Mahadevan A (2017) Is it really possible to predict the consistency of a pituitary adenoma preoperatively? Neurochirurgie 63:453–457. https://doi.org/10.1016/j.neuchi.2017.06.003CrossRefPubMed

45.

Pierallini A, Caramia F, Falcone C et al (2006) Pituitary macroadenomas: preoperative evaluation of consistency with diffusion-weighted MR imaging--initial experience. Radiology 239:223–231. https://doi.org/10.1148/radiol.2383042204CrossRefPubMed

46.

Shen M, Zhang Q, Liu W et al (2016) Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly. Neuroradiology 58:1057–1065. https://doi.org/10.1007/s00234-016-1728-4CrossRefPubMed

47.

Iuchi T, Saeki N, Tanaka M et al (1998) MRI prediction of fibrous pituitary adenomas. Acta Neurochir (Wien) 140:779–786. https://doi.org/10.1007/s007010050179CrossRefPubMed

48.

Bonneville F, Rivière L-D, Petersenn S et al (2018) MRI T2 signal intensity and tumor response in patients with GH-secreting pituitary macroadenoma: PRIMARYS post-hoc analysis. Eur J Endocrinol:EJE-18-0254.R2. https://doi.org/10.1530/EJE-18-0254

49.

Harward S, Harrison Farber S, Malinzak M et al (2018) T2-weighted images are superior to other MR image types for the determination of diffuse intrinsic pontine glioma intratumoral heterogeneity. Childs Nerv Syst ChNS Off J Int Soc Pediatr Neurosurg 34:449–455. https://doi.org/10.1007/s00381-017-3659-8CrossRef

50.

Nishioka H, Shibuya M, Ohtsuka K et al (2010) Endocrinological and MRI features of pituitary adenomas with marked xanthogranulomatous reaction. Neuroradiology 52:997–1002. https://doi.org/10.1007/s00234-010-0675-8CrossRefPubMed

51.

Sumislawski P, Huckhagel T, Krajewski KL et al (2023) Cystic versus non-cystic silent corticotrophic adenomas: clinical and histological analysis of 62 cases after microscopic transsphenoidal surgery-a retrospective, single-center study. Sci Rep 13:2468. https://doi.org/10.1038/s41598-023-29628-3CrossRefPubMedPubMedCentral

52.

Furtado SV, Saikiran NA, Ghosal N, Hegde AS (2010) Giant, solid, invasive prolactinoma in a prepubescent boy with gynecomastia. Pediatr Neurol 42:72–74. https://doi.org/10.1016/j.pediatrneurol.2009.08.005CrossRefPubMed

Titel: MRI and Trouillas’ grading system of pituitary tumors: the usefulness of T2 signal intensity volumetric values
verfasst von: Rosalinda Calandrelli
Fabio Pilato
Gabriella D’Apolito
Stefano Schiavetto
Marco Gessi
Quintino Giorgio D’Alessandris
Liverana Lauretti
Simona Gaudino
Publikationsdatum: 26.05.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Neuroradiology / Ausgabe 11/2023
Print ISSN: 0028-3940
Elektronische ISSN: 1432-1920
DOI: https://doi.org/10.1007/s00234-023-03162-5

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2023

Validation of a deep learning model for traumatic brain injury detection and NIRIS grading on non-contrast CT: a multi-reader study with promising results and opportunities for improvement

What to report in sellar tumor MRI? A nationwide survey among German pituitary surgeons, radiation oncologists, and endocrinologists

“Bunch of acai berries sign”: a new radiological sign in patients with CNS involvement in Chagas disease

Comparison of diffusion weighted imaging b0 with T2*-weighted gradient echo or susceptibility weighted imaging for intracranial hemorrhage detection after reperfusion therapy for ischemic stroke

Ghost twisting of the dual-layer flow-diverting stent